Novartis Aims For 14 New Blockbuster Drugs By End Of 2017

At an investor day presentation Nov. 8, Novartis discussed a pipeline expected to yield 18 regulatory decisions over the next 24 months. The Swiss pharma currently has 139 ongoing pipeline projects, including 73 NMEs.